"LinXis is proud to welcome Professor Dario Neri to its Advisory Board"


Our platinum-based Lx® linker offers a new paradigm for the manufacturing of antibody-drug conjugates.

Like a molecular super-glue, our proprietary Lx® Linker generates an extremely strong bond between drugs and antibody.

Taking its strength from a platinum core, the Lx® Linker confers unprecedented stability to the antibody-drug conjugates, which translates into a favorable safety and efficacy profile - much more favorable than competing products, which are known to lose their drugs before reaching the target cells. At the same time, the natural ability of platinum to bind drugs to antibodies makes for an extremely simple, efficient, and cost-effective manufacturing process.

Lx® technology offers a unique opportunity to generate effective, safe and affordable targeted medicines.

Building an antibody-drug conjugate with Lx® is a straightforward, two-step process. First, one end of the Linker couples to the drug. Then, the other end couples to the antibody. This coupling is driven entirely by the Linker's platinum core, and requires no pre-treatment of the antibody. We can precisely control the number of drugs coupled per antibody. Moreover, the process intermediates are stable, meaning that the steps can be performed at different places and at different times. Compared to other manufacturing technologies, these advantages are significant.